Zacks Investment Research upgraded shares of Arsanis (NASDAQ:ASNS) from a hold rating to a buy rating in a research report released on Thursday, March 15th. They currently have $27.00 price target on the stock.
According to Zacks, “Arsanis, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovering and developing monoclonal antibodies for the targeted immunotherapy of serious infections. The company’s product pipeline includes ASN100, ASN200, ASN300, ASN400 and ASN500 which are in preclinical stage. It operates primarily in the United States and Austria. Arsanis, Inc. is based in Waltham, United States. “
Several other brokerages have also issued reports on ASNS. Cantor Fitzgerald set a $26.00 price target on shares of Arsanis and gave the company a buy rating in a report on Thursday, March 15th. Cowen assumed coverage on shares of Arsanis in a research note on Monday, December 11th. They issued an outperform rating for the company. Piper Jaffray assumed coverage on shares of Arsanis in a research note on Monday, December 11th. They issued an overweight rating and a $23.00 target price for the company. ValuEngine raised shares of Arsanis from a strong sell rating to a sell rating in a research note on Friday, February 2nd. Finally, Citigroup assumed coverage on shares of Arsanis in a research report on Monday, December 11th. They set a buy rating and a $27.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $25.75.
NASDAQ:ASNS opened at $22.30 on Thursday. The company has a debt-to-equity ratio of 0.17, a current ratio of 7.45 and a quick ratio of 7.45. Arsanis has a 1 year low of $10.40 and a 1 year high of $28.69. The company has a market capitalization of $340.49 and a PE ratio of -1.37.
Arsanis (NASDAQ:ASNS) last posted its quarterly earnings data on Friday, March 9th. The company reported ($1.68) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.82). sell-side analysts anticipate that Arsanis will post -4.57 EPS for the current year.
Several hedge funds have recently modified their holdings of ASNS. Monashee Investment Management LLC acquired a new position in shares of Arsanis during the 4th quarter worth approximately $191,000. Sphera Funds Management LTD. acquired a new position in shares of Arsanis during the 4th quarter worth approximately $3,436,000. Landscape Capital Management L.L.C. acquired a new position in shares of Arsanis during the 4th quarter worth approximately $504,000. Finally, Millennium Management LLC acquired a new position in shares of Arsanis during the 4th quarter worth approximately $299,000. 69.45% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/08/arsanis-asns-upgraded-to-buy-at-zacks-investment-research.html.
Arsanis Company Profile
Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. Its lead product candidate is ASN100, a first-in-class mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia.
Get a free copy of the Zacks research report on Arsanis (ASNS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.